Cordlife Group Ltd
SGX:P8A
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.12
0.455
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SGD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cordlife Group Ltd
Cordlife Group Ltd
Cost of Revenue
Cordlife Group Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cordlife Group Ltd
SGX:P8A
|
Cost of Revenue
-S$17.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-2%
|
|
|
Q & M Dental Group (Singapore) Ltd
SGX:QC7
|
Cost of Revenue
-S$21.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Healthway Medical Corporation Ltd
SGX:5NG
|
Cost of Revenue
-S$26.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
T
|
Talkmed Group Ltd
SGX:5G3
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
HC Surgical Specialists Ltd
SGX:1B1
|
Cost of Revenue
-S$2.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
EUDA Health Holdings Ltd
NASDAQ:EUDA
|
Cost of Revenue
-$2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cordlife Group Ltd
Glance View
Cordlife Group Ltd. is an investment holding company, which engages in the provision of cord blood and cord lining banking services. The Company’s segments include Banking and Diagnostic. The Banking segment comprises the banking of samples, such as cord blood, cord lining and cord tissue. The Diagnostic segment comprises Metascreen, which is a metabolic screening test specially designed for newborn babies, a non-invasive prenatal testing service, and Eyescreen, a noninvasive pediatric eye-screening service. The cord blood and cord lining are collected, processed and stored in the various laboratories in the regions that the Company operates in. The firm offers a range of diagnostics services for the family, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
See Also
What is Cordlife Group Ltd's Cost of Revenue?
Cost of Revenue
-17.1m
SGD
Based on the financial report for Jun 30, 2024, Cordlife Group Ltd's Cost of Revenue amounts to -17.1m SGD.
What is Cordlife Group Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-2%
Over the last year, the Cost of Revenue growth was 8%. The average annual Cost of Revenue growth rates for Cordlife Group Ltd have been 1% over the past three years , 9% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet
